Amneal Pharmaceuticals, the 7th largest generic drug manufacturer in the U.S., announced today that it has entered into agreements with subsidiaries of Actavis, Inc. to purchase four generic products for cash consideration. One product is currently marketed in the U.S. by Actavis, two products have Abbreviated New Drug Applications currently awaiting regulatory approval, and one product has been approved but is not currently marketed pursuant to a settlement agreement. The closings of the purchase agreements are contingent upon the consummation of Actavis’ acquisition of Warner Chilcott plc.
The product currently marketed is Zenchent Fe™ (norethindrone acetate/ethinyl estradiol), the generic version of Femcon Fe™. Amneal expects to begin shipping Zenchent Fe immediately following the closing of the acquisition. The two products awaiting regulatory approval are norethindrone acetate/ethinyl estradiol, the generic version of Lo Loestrin ® Fe; and risedronate sodium, the generic version of Atelvia ®. The generic product approved but not currently marketed is norethindrone acetate/ethinyl estradiol, the generic equivalent of Loestrin ® 24 Fe.
